Overview

  • Product nameAnti-VEGF Receptor 2 antibody [RM0002-7A23]
    See all VEGF Receptor 2 primary antibodies
  • Description
    Rat monoclonal [RM0002-7A23] to VEGF Receptor 2
  • Specificityab51873 recognizes VEGFR2. No cross reactivity to VEGFR1 and VEGFR3.
  • Tested applicationsSuitable for: IHC-P, WB, IHC-Frmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Purified VEGFR2 extracellular domain (Mouse)

Properties

Applications

Our Abpromise guarantee covers the use of ab51873 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P Use at an assay dependent dilution. PubMed: 21245940
WB 1/200 - 1/800. Predicted molecular weight: 152 kDa.
IHC-Fr 1/50 - 1/100.

Target

  • FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
  • Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
  • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
  • Cellular localizationMembrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • CD309 antibody
    • CD309 antigen antibody
    • EC 2.7.10.1 antibody
    • Fetal liver kinase 1 antibody
    • FLK-1 antibody
    • FLK1 antibody
    • FLK1, mouse, homolog of antibody
    • Kdr antibody
    • Kinase insert domain receptor (a type III receptor tyrosine kinase) antibody
    • Kinase insert domain receptor antibody
    • KRD1 antibody
    • Ly73 antibody
    • Protein tyrosine kinase receptor FLK1 antibody
    • Protein-tyrosine kinase receptor flk-1 antibody
    • soluble VEGFR2 antibody
    • Tyrosine kinase growth factor receptor antibody
    • Vascular endothelial growth factor receptor 2 antibody
    • VEGFR 2 antibody
    • VEGFR antibody
    • VEGFR-2 antibody
    • VEGFR2 antibody
    • VGFR2_HUMAN antibody
    see all

References for Anti-VEGF Receptor 2 antibody [RM0002-7A23] (ab51873)

This product has been referenced in:
  • Singh N  et al. Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity. Blood 121:4242-9 (2013). ELISA ; Mouse . Read more (PubMed: 23476047) »
  • Duignan IJ  et al. Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models. Neoplasia 13:49-59 (2011). IHC-P ; Human . Read more (PubMed: 21245940) »

See all 2 Publications for this product

Product Wall

There are currently no Abreviews or Questions for ab51873.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"